Facts on DCTH's PHP System
Positive trial results, market advantages and platform technology.
Written by Douglas Estadt
Wall Street Media presents exclusive video of the internationally renowned Interventional Radiologist and Delcath’s Chief Medical Officer, Dr. Krishna Kandarpa, MD, Ph.D. Dr. Kandarpa discusses PHP’s extremely positive trial results and market advantages and potential. He also clarifies recent inaccuracies concerning PHP in the media.
- There are no requirements under Delcath’s SPA for enrollment minimums for either ocular or cutaneous melanoma
- Overall survival used only 20% of the time (2005-2007); progression free used 80% of the time
- Clinic breakdown populations are immaterial as there was no difference in response in patients with either ocular and cutaneous melanoma
- The market for this system will be far larger than some figures currently being inaccurately presented in the media: 80% of liver cancer cases are in Asia so those presenting figures for only cases in America are either somehow ignorant of this crucial fact, or behaving disingenuously
study was designed so that patients were allowed to crossover from the Best
Alternative Care group to the PHP group and 27 patients were saved due to
this humanitarian aspect of the trial
To hear more about DCTH, view the video below.
Visit Wall Street Media. We feature exclusive insights from the world's leading transparent investors.
Copyright © 2014 Microsoft. All rights reserved.
Traders might want to bite on BABA, but long-term investors have reasons to wait.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.